New drug trial targets root cause of rare, painful growth disorders
NCT ID NCT06975618
Summary
This early-stage study is testing an experimental drug called CYH33 for people with rare disorders that cause abnormal tissue and blood vessel overgrowth (PROS and PRVM). The main goals are to find a safe dose and see if the drug can shrink the overgrown lesions by at least 20% after 24 weeks. Researchers will also track changes in patients' pain levels and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Capital Institute of Pediatrics
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Plastic Surgery Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100144, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.